Cystic fibrosis: A changing clinical perspective

Australian and New Zealand Journal of Medicine

Volumn 27, Issue 1, 1997, Pages 6-11

  Sawyer, S M ^a,c   Robertson, C F ^b   Bowes, G ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ROYAL CHILDREN'S HOSPITAL   (Australia)

^c ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMILORIDE; DEOXYRIBONUCLEASE; GELSOLIN; TRANSMEMBRANE CONDUCTANCE REGULATOR;

CYSTIC FIBROSIS; GENE MUTATION; GENE THERAPY; HUMAN; LUNG TRANSPLANTATION; PHYSIOTHERAPY; REVIEW;

EID: 0030932751     PISSN: 00048291     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1445-5994.1997.tb00906.x     Document Type: Review

References (47)

1. The Australian Cystic Fibrosis Associations Federation National Data Registry. Annual Data Report, 1994.
2. Kerem E, Reisman J, Corey M, Canny GJ, Levison H. Prediction of mortality in patients with cystic fibrosis. N Engl JMed 1992; 326: 1187-90.
3. The Cystic Fibrosis Foundation Center Committee, Guidelines subcommittee. Cystic Fibrosis Foundation guidelines for patient services, evaluation, and monitoring in cystic fibrosis centres. Am J Dis Child 1990; 144: 1311-2.
4. WohIers AC. Data analytic methods of prognosis for cystic fibrosis. PhD thesis, University of Melbourne, 1996.
5. Phelan PD, Bowes G. Management of cystic fibrosis in Melbourne, Australia. Thorax 1991; 46: 383-4.
6. Rommens JR, lanuzzi MC, Kerem B et al. Identification of the cystic fibrosis gene: chromosomal walking and jumping. Science 1989; 245: 1059-65.
7. Riordan JR, Rommens JM, Kerem B et al. Identification of the cystic fibrosis gene: cloning and characterisation of the complementary DNA. Science 1989; 245: 1066-73.
8. Kerem B, Rommens JM, Buchanan JA et al. Identification of the cystic fibrosis gene: genetic analysis. Science 1989; 245: 1073-80.
9. Collins FC. Cystic fibrosis: molecular biology and therapeutic implications. Science 1992; 256: 774-9.
10. Dean M, Santis G. Heterogeneity in the severity of cystic fibrosis and the role of CFTR gene mutations. Hum Genet 1994; 93: 364-8.
11. Kerem E, Corey M, Kerem BS et al. The relation between genotype in cystic fibrosis - analysis of the most common mutation (AF508). N Engl J Med 1990; 323: 1517-22.
12. Anguiano A, Gates RD, Amos JA et al. Congenital bilateral absence of the vas deferens. A primarily genital form of cystic fibrosis. JAMA 1992; 267: 1794-7.
13. Colin AA, Sawyer SS, Mickel JE et al. Pulmonary function and clinical observations in males with congenital bilateral absence of the vas deferens. Chest 1996; 110; 440-5.
14. Highsmith WE, Burch LH, Zhou Z et al. A novel mutation in the cystic fibrosis gene in patients with pulmonary disease but normal sweat chloride concentrations. N Engl J Med 1994; 331: 974-80.
15. Welsh MJ, Smith AE. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell 1993; 73: 1251-4.
16. Smith JJ, Travis SM, Greenberg EP, Welsh MJ. Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell 1996; 85: 229-36.
17. Knowles MR, Church ML, Walters WE et al. A pilot study of aerosolized amiloride for the treatment of lung disease in cystic fibrosis. N Engl J Med 1990; 332: 1189-94.
18. Graham A, Hasani A, Alton EW et al. No added benefit from nebulized amiloride in patients with cystic fibrosis. EurRespir J 1993; 6: 1243-8.
19. Knowles MR, Clarke LL, Boucher RC. Activation by extracellular nucleotides of chloride secretion in the airway epithelia of patients with cystic fibrosis. N Engl J Med 1991; 325: 533-8.
20. Rosenstein BJ, Eigan H. Risks of alternate day prednisone in patients with cystic fibrosis. Pediatrics 1991; 87: 245-6.
21. Konstan MW, Byard PJ, Hoppel CL, Davis PB. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 1995; 332: 848-54.
22. Crystal RG. The gene as a drug. Nature Med 1995; 1: 15-7.
23. Alton EWFW, Middleton PG, Caplen NJ et al. Non-invasive liposome-mediated gene delivery can correct the ion transport defect in cystic fibrosis mutant mice. Nature Genet 1993; 5: 135-42.
24. Schreier H, Sawyer SM. Liposomal DNA vectors for cystic fibrosis gene therapy. Current applications, limitations and future directions. Avanced Drug Delivery Reviews 1996; 19: 73-87.
25. Rossman CM, Waldes R, Sampson D, New-house MT. Effect of chest physiotherapy on the removal of mucus in patients with cystic fibrosis. Am Rev Respir Dis 1982; 126: 131-5.
26. Pryor JA, Webber BA, Hodson ME, Batten JC. Evaluation of the forced expiratory technique as an adjunct to postural drainage in the treatment of cystic fibrosis. Br Med J 1979; 2: 417-8.
27. Chevaillier J. Autogenic drainage. In: Lawson D (Ed). Cystic fibrosis: horizons. Chichester, England: John Wiley, 1984; 235.
28. Falk M, Kelstrup M, Andersen JB, Kinoshita T, Falk P, Stovring S. Improving the ketchup bottle method with positive expiratory pressure in cystic fibrosis. Eur J Resp Dis 1984; 65: 423-32.
29. Pryor JA, Webber BA. Physiotherapy for cystic fibrosis. Which technique? Physiotherapy 1992; 78: 105-8.
30. Warwick WJ, Hansen LG. The long term effect of high frequency chest compression therapy on pulmonary complications of cystic fibrosis. Pediatr Pul 1991; 11: 265-71.
31. Williams MT. Chest physiotherapy and cystic fibrosis. Why is the most effective form of treatment still unclear? Chest 1994; 106: 1872-82.
32. Orenstein DM, Franklin BA, Doershuk CF et al. Exercise conditioning and cardiopulmonary fitness in cystic fibrosis. Effects of a supervised three month running program. Chest 1981; 80: 392-8.
33. Andreasson B, Jonson B, Kornfalt R, Nordmark E, Sandstrom S. Long term effects of physical exercise on working capacity and pulmonary function in cystic fibrosis. Acta Pediatr Scand 1987; 70: 70-5.
34. Nixon PA, Orenstein DM, Kelsey SF, Doershuk CF. The prognostic value of exercise testing in patients with cystic fibrosis. N Engl J Med 1992; 237: 1785-8.
35. Shak S, Capon DJ, Hellmiss R, Marsters SA, Baker CL. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. Proc Natl Acad Sci USA 1990; 87: 9188-92.
36. Fuchs HJ, Borowitz DS, Christiansen DH et al. Effect of aerosolized recombinant DNase on exacerbations of respiratory symptoms and on pulmonary function in cystic fibrosis. N Engl J Med 1994; 331: 637-42.
37. Vasconcellos CA, Allen PG, Wohl ME, Drazen JM, Janmey PA, Stossel TP. Reduction in viscosity of cystic fibrosis sputum in vitro by gelsolin. Science 1994; 263: 969-71.
38. Robinson M, Regnis JA, Bailey DL, King M, Bautovich GJ, Bye PT. Effect of hypertonic saline, amiloride and cough on mucociliary clearance in patients with cystic fibrosis. Am J Respir Crit Care Med 1996; 153: 1503-9.
39. Eng PA, Morton J, Douglass JA, Riedler J, Wilson J, Robertson CF. Efficacy of short-term ultrasonically nebulised hypertonic saline in patients with cystic fibrosis. Pediatr Pul 1996; 21: 77-83.
40. Yacoub MH, Banner NR, Khaghani A et al. Heart-lung transplantation for cystic fibrosis and subsequent domino heart transplantation. J Heart Transplant 1990; 9: 459-67.
41. Scott J, Higenbottam T, Hutter J et al. Heart-lung transplantation for cystic fibrosis. Lancet 1988; ii: 192-4.
42. Madden B, Radley-Smith R, Hodson M, Khaghani A, Yacoub M. Medium-results of heart and lung transplantation. J Heart Lung Transplant 1992; 11: S241-3.
43. Hosenpud JD, Novick RJ, Bennett LE, Keck BM, Fiol B, Daily OP. The Registry of the International Society for Heart and Heart-Lung Transplantation: Thirteenth official report - 1996. J Heart Lung Transplant 1996; 15: 655-74.
44. Elbourn JS, Shale DJ, Britton JR. Heart-lung transplantation in cystic fibrosis: predictions for the next decade in England and Wales. Respir Med 1994; 88: 135-8.
45. Cohen RG, Barr ML, Schenkel FA, DeMeester TR, Wells WJ, Starnes VA. Living related donor lobectomy for bilateral lobar transplantation in patients with cystic fibrosis. Ann Thor Surg 1994; 57: 1423-7.
46. Davis PB, Drumm M, Konstan MW. Cystic fibrosis. AmJResp CC Med 1996; 154: 1229-56.
47. Sawyer S. Reproductive health in young people with cystic fibrosis. Curr Opin Paed 1995; 7: 376-80.